Biogen Idec To Reduce Annual Operating Expenses By $200 Mil.-$300 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec’s strategic plan calls for divesting the psoriasis biologic Amevive (alefacept) and 17% workforce reductions, or 650 employees.
You may also be interested in...
Astellas Buys Amevive From Biogen Idec
Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties
Astellas Buys Amevive From Biogen Idec
Astellas will purchase Biogen Idec's psoriasis biologic Amevive (alefacept) for $60 mil. plus royalties
Biogen Idec Business Development Plan Includes Small Molecules For Oncology
The company expects the bulk of expenditures from a $200 mil. business development plan will go toward up-front milestones and new clinical costs for in-licensed drugs.